Advanced search
Publication Cover
Clinical Ophthalmology Volume 17, 2023 - Issue
Submit an article Journal homepage
236
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

Liesbeth Van Cleemput1 Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium;2 Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, BelgiumCorrespondence[email protected]
,
Freya Peeters1 Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium;2 Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, Belgium
&
Julie Jacob1 Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium;2 Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, Belgium
Pages 1077-1085 | Received 24 Jan 2023, Accepted 21 Mar 2023, Published online: 08 Apr 2023

References

  • Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738. doi:10.1016/S0140-6736(12)60282-7
  • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
  • Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
  • Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e16. doi:10.1016/S2214-109X(13)70145-1
  • Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
  • Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration. Ophthalmology. 2016;123(5):1080–1089. doi:10.1016/j.ophtha.2015.12.030
  • Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–1304. doi:10.1016/j.ophtha.2017.03.057
  • Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028
  • Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye. 2020;34(10):1726–1728. doi:10.1038/s41433-020-0853-9
  • Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi:10.1016/j.ophtha.2020.04.017
  • Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. doi:10.1016/j.ajoc.2020.100680
  • Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Retin Dis. 2020;4(4):269–279. doi:10.1177/2474126420930863
  • Jain A, Chea S, Matsumiya W, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;2020:18.
  • Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab. Ophthalmology. 2021;128(7):1050–1059. doi:10.1016/j.ophtha.2020.11.011
  • Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519–527. doi:10.1016/j.oret.2020.09.020
  • Novartis. Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program; 2021. Available from: https://www.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program. Accessed March 3, 2022.
  • Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraokulare Entzündungen bei Brolucizumab-Anwendung. Der Ophthalmologe. 2021;118(3):248–256. doi:10.1007/s00347-021-01321-8
  • Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007;9(3):90–95. doi:10.1109/MCSE.2007.55
  • Bulirsch LM, Sassmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;106:1288–1294. doi:10.1136/bjophthalmol-2020-318672
  • Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1):6759. doi:10.1038/s41598-021-86014-7
  • Enriquez AB, Baumal CR, Crane AM, et al. Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(4):441–448. doi:10.1001/jamaophthalmol.2020.7085
  • Schmouder R, Maciejewski B, Karle A, et al. Immunologic Features of Beovu®-Associated Retinal Vasculitis/Retinal Vascular Occlusion. Euretina Congress; 2021.
  • Jabs D, Nussenblatt R, Rosenbaum J, Becker M. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.